New pill tested to slow deadly lung scarring

NCT ID NCT06325696

Recruiting now Disease control Sponsor: National Institute of Environmental Health Sciences (NIEHS) Source: ClinicalTrials.gov ↗

Summary

This study is testing a pill called H01 (hymecromone) in adults with progressive interstitial lung disease, a condition that causes severe, often fatal scarring of the lungs. Over 5 months, about 37 participants will take the drug for 12 weeks to see if it reduces a key marker of scarring and is safe. The main goal is to see if the treatment can help control the disease by lowering levels of a substance linked to lung damage.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for IDIOPATHIC PULMONARY FIBROSIS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

NIEHS Clinical Research Unit (CRU)
RECRUITING

Research Triangle Park, North Carolina, 27709, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

IDIOPATHIC PULMONARY FIBROSIS INTERSTITIAL LUNG DISEASE LUNG DISEASES, INTERSTITIAL